Therapy
Teplizumab
Anti-CD3 Fc-silent mAb (Fc modified to prevent ADCC/CDC): binds CD3ε on T cells without Fc receptor engagement → T cell exhaustion/regulatory programme in autoreactive Th1 cells driving insulitis → shifts Th1:Treg ratio in islets.
Also called: Tzield, anti-CD3 Fc-silent, OKT3 derivative
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 3 and is affected by 2 concepts — mostly 1 receptor, 1 disease, 2 trial.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
TN10 TRIAL (2019/FDA 2022): first drug to delay an autoimmune disease.
Its connections at a glance
Each dot is a concept directly linked to Teplizumab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I013 · concept status: established. Select any connection above to inspect evidence for that specific link.